MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-21-2022
Applied Genetic Technologies Corporation Operating Income 2011-2026 | AGTC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.7 M | -18.4 M | -15.1 M | -4.35 M | -22.4 M | 1.9 M | -2.09 M | -24.5 M | -12.6 M | -3.59 M | -2.06 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.9 M | -24.5 M | -11 M |
Quarterly Operating Income Applied Genetic Technologies Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -17.3 M | - | -13.6 M | -18.4 M | -16.4 M | -34.9 M | -14.5 M | -15.1 M | -15.1 M | -15.1 M | -15.1 M | -8.93 M | -12 M | -8.93 M | -12 M | -4.67 M | 756 K | -4.67 M | 756 K | -6.24 M | -1.67 M | -6.24 M | -1.67 M | 2.38 M | 3.62 M | 2.15 M | 3.39 M | 2.87 M | -9.21 M | 2.87 M | -9.21 M | -4.7 M | -5.41 M | -4.7 M | -5.41 M | -2.9 M | -1.97 M | -1.29 M | -951 K | -796 K | -560 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.62 M | -34.9 M | -6.77 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aligos Therapeutics
ALGS
|
-88 M | $ 7.92 | -0.94 % | $ 78.3 M |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Precision BioSciences
DTIL
|
-43.7 M | $ 6.73 | 0.9 % | $ 25.9 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 2.15 | -0.69 % | $ 447 M | USA |
 |
Evogene Ltd.
EVGN
|
-31 M | $ 0.81 | -0.33 % | $ 27.9 M |  Israel |
 |
BioNTech SE
BNTX
|
15.3 B | $ 97.86 | 2.47 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 20.29 | -0.39 % | $ 948 M | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.42 | 5.22 % | $ 155 M | USA |
 |
Genmab A/S
GMAB
|
2.64 B | $ 28.24 | -0.04 % | $ 18 B |  Danmark |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.14 | -0.85 % | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
GT Biopharma
GTBP
|
-12.4 M | $ 0.36 | -3.5 % | $ 1.98 M | USA |
 |
Halozyme Therapeutics
HALO
|
469 M | $ 67.79 | -0.05 % | $ 8.12 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.42 | 1.07 % | $ 365 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.96 | 1.37 % | $ 4.87 M | Israel |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.15 | 1.72 % | $ 444 M | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 24.3 | 0.37 % | $ 3.09 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 28.82 | -0.24 % | $ 1.66 B | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 32.37 | 0.4 % | $ 2.15 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.52 | 1.68 % | $ 405 M | Britain |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
ImmuCell Corporation
ICCC
|
1.65 M | $ 7.24 | 2.33 % | $ 65.3 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
|
Immatics N.V.
IMTX
|
-86.3 M | $ 10.61 | 1.73 % | $ 668 M | Germany |
 |
Incyte Corporation
INCY
|
1.51 B | $ 96.66 | 0.61 % | $ 18.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.58 | 1.18 % | $ 16.2 M | USA |